title: Outcomes in 45 patients with statin-associated myopathy.
abstract: BACKGROUND
  Published studies regarding statin-associated myopathy may describe more dramatic patient presentations, potentially leading to inaccurate characterization of the condition. Furthermore, long-term outcomes and responses to statin rechallenge in patients with statin-associated myopathy are largely unknown.
  
  
  METHODS
  The University of Wisconsin Hospital and Clinics Medical Informatics Department identified 437 patients with International Classification of Diseases, Ninth Revision codes potentially representing cases of statin-associated myopathy from more than 13 years of inpatient and outpatient data; 45 of these individuals were diagnosed as having statin-associated myopathy. Using a standardized form, 2 researchers abstracted all the case records to define the clinical course of statin-induced myopathy.
  
  
  RESULTS
  The mean (SD) duration of statin therapy before symptom onset was 6.3 (9.8) months. Resolution of muscle pain occurred a mean (SD) of 2.3 (3.0) months after discontinuation of statin therapy. Six patients (13%) were hospitalized for the management of rhabdomyolysis; 2 had reversible renal dysfunction, and 1 with preexisting renal insufficiency subsequently began lifelong dialysis. Hospitalized patients developed myopathy more quickly after initiating statin therapy (1.3 vs 7.1 months; P = .048) and were more likely to be taking concomitant medications known to increase the risk of statin-associated myopathy (P = .03). Thirty-seven patients received another statin after an episode of statin-associated myopathy; 21 (57%) reported recurrent muscle pain, whereas 16 (43%) tolerated other statins without recurrent symptoms.
  
  
  CONCLUSIONS
  Patients with statin-associated myopathy experienced full resolution of muscle pain on cessation of statin therapy. Although no deaths occurred, 13% of the patients required hospitalization for rhabdomyolysis. Recurrent muscle pain was common on statin rechallenge.
authors.affiliation: Rheumatology Section, University of Wisconsin Medical School, H6/363 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA. keh@medicine.wisc.edu
authors.forename: Karen E
authors.initials: KE
authors.lastname: Hansen
authors.forename: Julie P
authors.initials: JP
authors.lastname: Hildebrand
authors.forename: Edwin E
authors.initials: EE
authors.lastname: Ferguson
authors.forename: James H
authors.initials: JH
authors.lastname: Stein
mesh_terms: D000367:Age Factors; D003402:Creatine Kinase / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced*; D010146:Pain / Q000139:chemically induced*; D020127:Recovery of Function; D012008:Recurrence; D051437:Renal Insufficiency / Q000097:blood; D012189:Retrospective Studies; D012206:Rhabdomyolysis / Q000139:chemically induced / Q000628:therapy
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D003402:Creatine Kinase